AlphaRx Announces Results On Highly Effective, Novel, Topical Non-Steroidal Anti-Inflammatory Formulations.Business Editors/Health & Medical Writers RICHMOND HILL, Ontario--(BW HealthWire)--May 14, 2002 AlphaRx (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :ALRX) is pleased to announce data and results on its new topical drug Topical drug Drug or medication applied to a specific area of the skin and affecting only the area to which it is applied. Mentioned in: Minoxidil delivery formulation, as compiled by AlphaRx's Chief Scientist Joseph Schwarz, Ph.D. and Dr. Peter Carlen, senior scientist with the Toronto Western Research Institute, neurologist with the Krembil Neuroscience Centre at the Toronto Western Hospital The Toronto Western Hospital is located at the corner of Bathurst Street and Dundas Street West in Toronto, Canada. It is part of the University Health Network. TWH has 256 beds, with 46,000 visits to its emergency department annually. , and professor of medicine (neurology) at the University Of Toronto Research at the University of Toronto has been responsible for the world's first electronic heart pacemaker, artificial larynx, single-lung transplant, nerve transplant, artificial pancreas, chemical laser, G-suit, the first practical electron microscope, the first cloning of T-cells, . The experimental design was repeated and the results were consistently reproducible in comparing a number of formulations using AlphaRx's drug delivery formulation with some well-known commercial topical anti-inflammatory creams. The data supported the conclusion that AlphaRx's new topical formulations possess enhanced anti-inflammatory activity when compared to well-known commercial brands currently in the market. The research was conducted in the laboratories of Dr. Carlen, under a Sponsored Research Agreement between NeuroProtection Inc. (NPI NPI National Provider Identifier, see there ) and the University Health Network (UHN UHN United Hackers Network (hacker group) UHN Unit Hub Node ). AlphaRx has engaged NeuroProtection Inc. in a Research and Consulting Agreement under which NPI is designing a pre-clinical development program and clinical development strategy for AlphaRx's proprietary drug delivery system. NPI is conducting in-vivo investigations of compounds for enhanced delivery for site inflammation, brain inflammation, aging and neuroprotection. Some of the research is implemented via NPI's Sponsored Research Agreement with the University Health Network. The investigational compounds include Alpha Rx's proprietary BCD (Binary Coded Decimal) The storage of numbers in which each decimal digit is converted into binary and is stored in a single character or byte. For example, a 12-digit number would take 12 bytes. See binary numbers. drug delivery system in combination with standard Non-Steroidal Anti-inflammatory Drugs Non-steroidal anti-inflammatory drugs (NSAIDs) Aspirin, ibuprofen, naproxen, and many others. Mentioned in: Mastocytosis (NSAIDS). On-going work will include additional investigations with these compounds and with NeuroProtection Inc.'s proprietary MPCB MPCB Maharashtra Pollution Control Board (India) MPCB Motor Protection Circuit Breaker neuro-protective agents. The study demonstrated that AlphaRx's new topical formulations, comprised of safe, well known delivery components, are stable, with low-irritancy, possess a high efficacy in the local delivery of biologically active compounds. Comparative anti-inflammatory activity of topical formulations included ARX cream (16% MeSal), Ben Gay(TM) "extraforte" cream (30% MeSal), Voltaren Emugel(TM), ARX cream (6-MC). The proprietary formulations can be readily manufactured with available industry-standard pharmaceutical equipment. AlphaRx's topical drug delivery formulation, utilizes natural and safe carrier components. This drug delivery vehicle significantly increases drug loading through a unique combination of polarity and hydrophobicity of the carrier components. Additional refinements in this field by AlphaRx have resulted in the capability of formulating stable submicron emulsions without the use of high-pressure homogenizers. Such "self-emulsifying" formulations containing Non-Steroidal Anti-inflammatory Drugs (NSAIDs) have been tested in non-infection, inflammatory animal models, in order to compare the relative activity of these drugs in traditional versus enhanced delivery vehicles. These in-vivo experiments have been carried out at the Toronto Western Hospital/University Health Network. The experimental protocol was peer reviewed and approved by the ethics review committee. The experimental results are consistent and reproducible, supporting the suggestion that AlphaRx's new topical formulations possess superior anti- inflammatory activity. For example, AlphaRx's ARX cream with 16% Methylsalicylate produced a three-fold reduction in edema edema (ĭdē`mə), abnormal accumulation of fluid in the body tissues or in the body cavities causing swelling or distention of the affected parts. volume at peak activity, when compared to Pfizer's well-known and popular BenGay(TM) "Extra Forte" OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). cream (30% Methylsalicylate). All AlphaRx compositions showed similar enhanced anti-inflammatory activity when compared to other test formulations. Data was prepared Q-1 2002. About AlphaRx AlphaRx is engaged in the development of novel formulations of drugs that are insoluble or poorly soluble in water. AlphaRx's broad product pipeline consists of carefully selected, currently marketed drugs, which, through the application of its proprietary BCD drug delivery technology, offer improved medical benefits over existing products with a strong commercial potential. About UHN University Health Network is a major landmark in Canada's health care system and a teaching hospital of the University of Toronto. Building on the strengths and reputation of each of these three remarkable hospitals, Toronto Western Hospital, Toronto General Hospital The Toronto General Hospital (TGH), part of the University Health Network, is a major teaching hospital in downtown Toronto, Canada. It is located in the Discovery District, directly north of the Hospital for Sick Children, across Gerrard Street West, and east of Princess , and Princess Margaret Hospital There are several Princess Margaret Hospitals :
About NeuroProtection Inc. NeuroProtection Inc. is a Toronto-based R&D company actively engaged in the discovery and development of novel agents for development as pharmaceuticals with neuroprotective applications. The company houses several patents and patent applications covering its proprietary MPCB technology for neuroprotection and has other Intellectual Property in process. FORWARD LOOKING STATEMENTS: This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company. Econ Investor Relations Connie Linder Toll free: 888-368-8705 Email: clinder@investorideas.com |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion